National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, WA, USA.
Institute for Healthy Aging and Lifespan Studies, School of Urban and Regional Planning, Florida Atlantic University, Boca Raton, FL, USA.
Lab Invest. 2019 Jul;99(7):1049-1055. doi: 10.1038/s41374-019-0186-0. Epub 2019 Feb 1.
Primary age-related tauopathy (PART) is increasingly recognized as a pathologic entity distinct from Alzheimer's disease (AD). Given that the diagnosis of PART is an autopsy diagnosis, it is unclear how PART is perceived in clinical practice. Thus, we investigated the presumptive primary and contributing diagnoses in individuals who had cognitive impairment while alive and who met neuropathologic criteria for PART at autopsy. We also compared these clinical diagnoses for people with PART to those with AD neuropathology (ADNP). We used data on 1354 participants from the National Alzheimer's Coordinating Center, restricting to those with no neuritic plaques (PART) or moderate/frequent neuritic plaques (ADNP); clinical visit within two years of autopsy; and mild cognitive impairment (MCI) or dementia at last visit. To assess if PART participants were less likely to receive a clinical diagnosis of AD at their last visit prior to autopsy, we used logistic regression, controlling for age, sex, education, and APOE ε4 status. There were 161 PART individuals (n = 49 MCI; n = 112 dementia) and 1193 individuals with ADNP (n = 75 MCI; n = 1118 dementia). Primary clinical diagnosis of AD was more common in those with ADNP (MCI: 69%; demented: 86%) than PART (MCI: 57%; demented: 52%). In the adjusted analysis, primary and contributing clinical diagnoses of AD remained less likely in PART vs. ADNP participants with dementia (OR: 0.22, 95% CI: 0.13-0.38). This study suggests that clinicians recognize a distinction in the clinical presentation between PART and ADNP, diagnosing AD less frequently in those with PART. Nonetheless, clinical AD was diagnosed greater than 50% of the time in PART participants with MCI or dementia. Ante-mortem criteria for diagnosis of PART need to be established, as PART is a neuropathological entity that is distinct from AD and has its own clinical and cognitive outcomes.
原发性年龄相关性 tau 病(PART)越来越被认为是一种与阿尔茨海默病(AD)不同的病理实体。鉴于 PART 的诊断是尸检诊断,尚不清楚 PART 在临床实践中的认知情况。因此,我们调查了生前认知障碍且尸检符合 PART 病理标准的个体的推定原发性和促成性诊断。我们还将这些 PART 患者的临床诊断与 AD 神经病理学(ADNP)患者进行了比较。我们使用了来自国家阿尔茨海默病协调中心的 1354 名参与者的数据,限制为无神经原纤维缠结(PART)或中度/频繁神经原纤维缠结(ADNP);尸检前两年的临床就诊;最后一次就诊时为轻度认知障碍(MCI)或痴呆。为了评估 PART 参与者在尸检前的最后一次就诊时是否不太可能被诊断为 AD,我们使用了逻辑回归,控制了年龄、性别、教育程度和 APOE ε4 状态。共有 161 名 PART 患者(49 名 MCI;112 名痴呆)和 1193 名 ADNP 患者(75 名 MCI;1118 名痴呆)。ADNP 患者(MCI:69%;痴呆:86%)的主要临床诊断为 AD 的比例高于 PART 患者(MCI:57%;痴呆:52%)。在调整后的分析中,PART 与 ADNP 患者的痴呆相比,原发性和促成性 AD 的临床诊断仍然不太可能(OR:0.22,95%CI:0.13-0.38)。这项研究表明,临床医生在 PART 和 ADNP 之间的临床表现上有所区分,在 PART 患者中诊断 AD 的比例较低。尽管如此,PART 患者中 MCI 或痴呆的临床 AD 诊断率仍超过 50%。需要建立 PART 的生前诊断标准,因为 PART 是一种与 AD 不同的神经病理学实体,具有自己的临床和认知结果。